Consistent with these results, we found that a hallmark of the EMT process- E-cadherin protein levels were increased, whereas N-cadherin and Vimentin protein levels were decreased in miR-137-overexpressing GBM cells with TMZ treatment. The gene discussed is CDH2; the disease is glioblastoma.